Help patients get access to lorlatinib

ALK Positive Canada is gathering support from oncologists and other clinicians to advocate for equitable access to lorlatinib for ALK-positive lung cancer patients needing second and subsequent lines of treatment.

Please add your name below to show your support. It will take less than 30 seconds and no login is required. If you have any questions, send us a message.

Your submission could not be saved. Please try again.

Thank you for supporting ALK-positive patients. Your voice brings us closer to equitable care.

First name

Last name

Email address

Institution / Hospital / Clinic

Location

I consent to share my name and email with government officials for this petition

Language

I also wish to subscribe to your newsletter